- Home
- ENLT vs PTGX Comparison
ENLT vs PTGX Comparison
Compare ENLT & PTGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENLT
- PTGX
- Stock Information
- Founded
- ENLT 2008
- PTGX 2006
- Country
- ENLT Israel
- PTGX United States
- Employees
- ENLT N/A
- PTGX N/A
- Industry
- ENLT
- PTGX Biotechnology: Pharmaceutical Preparations
- Sector
- ENLT
- PTGX Health Care
- Exchange
- ENLT Nasdaq
- PTGX Nasdaq
- Market Cap
- ENLT 3.0B
- PTGX 3.3B
- IPO Year
- ENLT 2023
- PTGX 2016
- Fundamental
- Price
- ENLT $25.49
- PTGX $55.15
- Analyst Decision
- ENLT Buy
- PTGX Strong Buy
- Analyst Count
- ENLT 4
- PTGX 9
- Target Price
- ENLT $21.75
- PTGX $67.11
- AVG Volume (30 Days)
- ENLT 33.1K
- PTGX 790.5K
- Earning Date
- ENLT 08-06-2025
- PTGX 08-05-2025
- Dividend Yield
- ENLT N/A
- PTGX N/A
- EPS Growth
- ENLT 90.47
- PTGX N/A
- EPS
- ENLT 0.98
- PTGX 0.86
- Revenue
- ENLT $397,296,000.00
- PTGX $207,801,000.00
- Revenue This Year
- ENLT $355.90
- PTGX N/A
- Revenue Next Year
- ENLT $42.83
- PTGX $53.09
- P/E Ratio
- ENLT $26.21
- PTGX $63.95
- Revenue Growth
- ENLT 44.42
- PTGX N/A
- 52 Week Low
- ENLT $14.01
- PTGX $32.50
- 52 Week High
- ENLT $27.16
- PTGX $60.60
- Technical
- Relative Strength Index (RSI)
- ENLT 59.26
- PTGX 56.72
- Support Level
- ENLT $24.80
- PTGX $51.55
- Resistance Level
- ENLT $27.16
- PTGX $57.73
- Average True Range (ATR)
- ENLT 0.45
- PTGX 1.74
- MACD
- ENLT -0.15
- PTGX -0.07
- Stochastic Oscillator
- ENLT 37.22
- PTGX 69.13
About ENLT Enlight Renewable Energy Ltd.
Enlight Renewable Energy Ltd develops, finances, constructs, owns, and operates utility-scale renewable energy projects. The company's operating segments are the MENA segment, Europe segment, U.S.A segment, and Others. It generates the majority of its revenue from the Europe segment, which produces its revenue from the sale of the electricity that is produced through wind energy and solar energy in Europe.
About PTGX Protagonist Therapeutics Inc.
Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.